Author

Zhang Zhang

Institution: BeOne Medicines (Switzerland)

Observed institutions: Central South University, Peking University Cancer Hospital, Hunan Cancer Hospital, BeOne Medicines (Switzerland), Renmin University of China

ORCID: 0000-0003-4188-0238

Observed ORCID: 0000-0003-4188-0238

OpenAlex ID: A5048347678

Neoadjuvant immunotherapy in squamous cell carcinoma of the head and neck: current evidence and future perspectives

2025 · Bocheng Zhang, Haolei Tan, et al. · Molecular Cancer · 16

Doubly robust estimation of optimal dynamic treatment regimes with multicategory treatments and survival outcomes

2022 · Zhang Zhang, Danhui Yi, et al. · Statistics in Medicine · 9

PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis

2026 · Yushang Yang, Xiaolong Yan, et al. · Clinical Cancer Research · 3

Data from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis

2026 · Yushang Yang, Xiaolong Yan, et al.

Supplementary Figure S4 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis

2026 · Yushang Yang, Xiaolong Yan, et al.

Supplementary Figure S2 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis

2026 · Yushang Yang, Xiaolong Yan, et al.

Supplementary Figure S6 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis

2026 · Yushang Yang, Xiaolong Yan, et al.

Supplementary Figure S1 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis

2026 · Yushang Yang, Xiaolong Yan, et al.

Supplementary Figure S5 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis

2026 · Yushang Yang, Xiaolong Yan, et al.

Supplementary Figure S3 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis

2026 · Yushang Yang, Xiaolong Yan, et al.

Supplementary Material S2 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis

2026 · Yushang Yang, Xiaolong Yan, et al.

Supplementary Tables S1-S15 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis

2026 · Yushang Yang, Xiaolong Yan, et al.

Supplementary Material S1 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis

2026 · Yushang Yang, Xiaolong Yan, et al.

Reply to: “ NOTCH1 : A Potential New Biomarker in the Era of Immunotherapy?” and “Caution in Interpreting NOTCH1 Mutation as a Predictive Biomarker of Tislelizumab Response in Esophageal Squamous Cell Carcinoma”

2025 · Zhihao Lu, Wenting Du, et al. · Journal of Clinical Oncology

Works count: 14

Citation count: 28

H-index: 3

I10-index: 1